Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

H Vestergaard; S Lund; O Pedersen; Henrik Vestergaard

Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

H Vestergaard, S Lund, O Pedersen, Henrik Vestergaard

Department of Immunology and Microbiology

24 Citations (Scopus)

Abstract

Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.

Original language	English
Journal	Journal of Internal Medicine
Volume	250
Issue number	5
Pages (from-to)	406-14
Number of pages	9
ISSN	0954-6820
Publication status	Published - Nov 2001

Keywords

Adolescent
Adult
Apolipoproteins B
Body Mass Index
Diabetes Complications
Diabetes Mellitus
Fatty Acids, Nonesterified
Humans
Hyperglycemia
Hypoglycemic Agents
Insulin
Insulin Resistance
Male
Mutation
Plasminogen Activator Inhibitor 1
Receptor, Insulin
Thiazoles
Thiazolidinediones
Triglycerides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. / Vestergaard, H; Lund, S; Pedersen, O et al.

In: Journal of Internal Medicine, Vol. 250, No. 5, 11.2001, p. 406-14.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{646834b7c51d48368ed7d35537d7638b,

title = "Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism",

abstract = "Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.",

keywords = "Adolescent, Adult, Apolipoproteins B, Body Mass Index, Diabetes Complications, Diabetes Mellitus, Fatty Acids, Nonesterified, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Mutation, Plasminogen Activator Inhibitor 1, Receptor, Insulin, Thiazoles, Thiazolidinediones, Triglycerides",

author = "H Vestergaard and S Lund and O Pedersen and Henrik Vestergaard",

year = "2001",

month = nov,

language = "English",

volume = "250",

pages = "406--14",

journal = "Acta Medica Scandinavica",

issn = "0955-7873",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

AU - Vestergaard, H

AU - Lund, S

AU - Pedersen, O

AU - Vestergaard, Henrik

PY - 2001/11

Y1 - 2001/11

N2 - Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.

AB - Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.

KW - Adolescent

KW - Adult

KW - Apolipoproteins B

KW - Body Mass Index

KW - Diabetes Complications

KW - Diabetes Mellitus

KW - Fatty Acids, Nonesterified

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Insulin

KW - Insulin Resistance

KW - Male

KW - Mutation

KW - Plasminogen Activator Inhibitor 1

KW - Receptor, Insulin

KW - Thiazoles

KW - Thiazolidinediones

KW - Triglycerides

M3 - Journal article

C2 - 11887975

SN - 0955-7873

VL - 250

SP - 406

EP - 414

JO - Acta Medica Scandinavica

JF - Acta Medica Scandinavica

IS - 5

ER -

Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

Abstract

Keywords

UN SDGs

Fingerprint

Cite this